Edition:
India

Ionis Licenses Hepatitis B Program To GSK


Tuesday, 27 Aug 2019 

Aug 27 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS LICENSES HEPATITIS B PROGRAM TO GSK.IONIS PHARMACEUTICALS INC - GSK EXERCISES OPTION TO LICENSE PROGRAM FOLLOWING POSITIVE PHASE 2 RESULTS.IONIS PHARMACEUTICALS INC - UNDER AGREEMENT, CO IS ELIGIBLE TO RECEIVE LICENSE FEES, MILESTONE PAYMENTS UP TO $262 MILLION, INCLUDING $25 MILLION LICENSE FEE.IONIS PHARMACEUTICALS INC - ALSO ELIGIBLE TO RECEIVE TIERED ROYALTIES IN LOW DOUBLE DIGITS ON NET SALES AS A PART OF LICENSING AGREEMENT.